Hello and Welcome to Patientsville.com, Your Source for all EFALIZUMAB information. We are dedicated to provide You with EFALIZUMAB safety information. Learn about EFALIZUMAB serious adverse events reported to Food and Drug Administration (FDA).
Medications A-Z: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
EFALIZUMAB Safety Reports
Total EFALIZUMAB reports: 66.EFALIZUMAB FDA safety alerts: 2005 .
Reported deaths: 7 Reported hospitalizations: 48.
Take EFALIZUMAB Side Effects Survey or Share Your EFALIZUMAB Story. Read More Here.
Health Professional from AUSTRIA reported EFALIZUMAB problem on Dec 22, 2006. Male patient, 63 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: epididymitis, hydrocele, spermatocele. EFALIZUMAB dosage: 0.7 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with HYDROCHLOROTHIAZIDE, FUROSEMIDE, OLMESARTAN, SIMVASTATIN, ALLOPURINOL, ETOFYLLINE, CAPTOPRIL. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Jan 03, 2007. Female patient, 61 years of age, weighting 205.0 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: papillary thyroid cancer. EFALIZUMAB dosage: 1 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with SYNTHROID, CYTOMEL. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Jan 05, 2007. Female patient, 68 years of age, weighting 205.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: ascites, cardiomegaly, clostridium difficile colitis, clostridium difficile sepsis, diverticulum, gastrointestinal infection, haematochezia, haematocrit decreased, haemoglobin decreased. EFALIZUMAB dosage: 125 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with NORVASC, DETROL LA, LASIX, ACCUPRIL, HYDROCHLOROTHIAZIDE, ACTOS, SINGULAIR. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED STATES on Jan 26, 2007. Female patient, 68 years of age, weighting 205.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: ascites, cardiomegaly, chest x-ray abnormal, clostridium difficile colitis, clostridium difficile sepsis, diverticulum, haematochezia, haemorrhoids, heart rate increased. EFALIZUMAB dosage: 125 MG, 1/WEEK, SUBCUTANEOUS; 1.25ML, 1/WEEK,. During the same period patient was treated with TOPICAL STEROIDS, NORVASC, DETROL LA, LASIX, ACCUPRIL, HYDROCHLOROTHIAZIDE, ACTOS. Patient was hospitalized. Patient recovered.
Health Professional from SWITZERLAND reported EFALIZUMAB problem on Jan 29, 2007. Male patient, 31 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: ventricular extrasystoles. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED KINGDOM on Feb 07, 2007. Male patient, 52 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, deep vein thrombosis, dermatitis exfoliative, gait disturbance, impetigo, pain in extremity, refusal of treatment by patient. EFALIZUMAB dosage: 0.142 MG/KG, UNK, SUBCUTANEOUS. During the same period patient was treated with CYCLOSPORINE. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Feb 22, 2007. Female patient, 23 years of age, weighting 141.1 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: pneumonitis. EFALIZUMAB dosage: 1 MG, 1/WEEK, SUBCUTANEOUS. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED STATES on Mar 02, 2007. Male patient, 78 years of age, weighting 156.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: hepatic neoplasm malignant, splenomegaly, varices oesophageal. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with METHOTREXATE, ADALIMUMAB, LISINOPRIL, DOXORUBICIN. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Mar 07, 2007. Male patient, 59 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: pemphigoid. EFALIZUMAB dosage: unknown. During the same period patient was treated with ETANERCEPT. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Mar 29, 2007. Male patient, 31 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: demyelinating polyneuropathy, guillain-barre syndrome. EFALIZUMAB dosage: 1 MILLIGRAM/KILOGRAM ONCE WEEKLY SQ. Patient was hospitalized and became disabled. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Mar 20, 2007. Male patient, 59 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, blister, pemphigoid, pruritus, rash erythematous, rash pustular. EFALIZUMAB dosage: unknown. During the same period patient was treated with ETANERCEPT. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from SWITZERLAND on Mar 22, 2007. Male patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: myocardial infarction. EFALIZUMAB dosage: 0.186 ML, 1/WEEK. During the same period patient was treated with ACETYLSALICYLIC ACID SRT, VALSARTAN AND HYDROCHLOROTHIAZIDE, SIMVASTATIN, INSULIN. Patient died on 02/20/2007.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Mar 27, 2007. Male patient, 78 years of age, weighting 156.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: hepatic neoplasm malignant, splenomegaly, varices oesophageal. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with METHOTREXATE, ADALIMUMAB, LISINOPRIL, DOXORUBICIN. Patient recovered.
EFALIZUMAB problem was reported by a Physician from SWITZERLAND on Apr 18, 2007. Female patient was diagnosed with psoriasis, platelet aggregation and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: cerebellar infarction. EFALIZUMAB dosage: 0.8 ML, 1/WEEK. Patient was hospitalized. Patient recovered.
Physician from SWITZERLAND reported EFALIZUMAB problem on Apr 23, 2007. Female patient was diagnosed with psoriasis, hypertension and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: abdominal strangulated hernia, duodenal ulcer, ovarian enlargement, small intestinal obstruction, spinal fusion surgery, wound dehiscence. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK. During the same period patient was treated with DOXAZOSIN MESYLATE, DOXAZOSIN MESYLATE. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Apr 18, 2007. Female patient, weighting 141.1 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: pneumonitis. EFALIZUMAB dosage: 1 MG, 1/WEEK. During the same period patient was treated with BIRTH CONTROL S. Patient recovered.
Physician from SWITZERLAND reported EFALIZUMAB problem on Apr 27, 2007. Male patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: subdural haematoma. EFALIZUMAB dosage: 1 ML, 1/WEEK. During the same period patient was treated with ACETYLSALICYLIC ACID SRT. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on May 04, 2007. Female patient, weighting 205.4 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: clostridium difficile colitis. EFALIZUMAB dosage: 125 MG, 1/WEEK. During the same period patient was treated with NORVASC, DETROL LA, LASIX, ACCUPRIL, HYDROCHLOROTHIAZIDE, ACTOS. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED KINGDOM reported EFALIZUMAB problem on June 08, 2007. Male patient, 35 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthritis, hepatitis, psoriasis. EFALIZUMAB dosage: unknown. Patient recovered.
EFALIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on June 18, 2007. Male patient, weighting 197.8 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: aphasia. EFALIZUMAB dosage: 0.08 MG, 1/WEEK. During the same period patient was treated with TOPICAL STEROID, KETOCONAZOLE. Patient recovered.
Physician from MEXICO reported EFALIZUMAB problem on June 28, 2006. Female patient, 72 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: anxiety, condition aggravated, insomnia, psoriasis, suicidal ideation. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from SWITZERLAND on June 29, 2006. Male patient, 46 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, arthritis, asthenia, asthma, basophil count increased, blood potassium increased, condition aggravated, eosinophil count increased, hypertension. EFALIZUMAB dosage: 0.142 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
Health Professional from BRAZIL reported EFALIZUMAB problem on June 28, 2006. Male patient, 66 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: abnormal behaviour, acute prerenal failure, autoimmune disorder, dialysis, gait disturbance, hallucination, headache, influenza like illness, leukocytosis. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with ENALAPRIL MALEATE. Patient was hospitalized. Patient died on 06/09/2005.
EFALIZUMAB problem was reported by a Consumer or non-health professional from BRAZIL on June 28, 2006. Male patient, 56 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: benign prostatic hyperplasia, condition aggravated, erectile dysfunction, prostate cancer, prostatic specific antigen increased, psoriasis. EFALIZUMAB dosage: 0.8 ML, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Physician from UNITED STATES reported EFALIZUMAB problem on July 07, 2006. Female patient, 26 years of age, weighting 240.3 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. EFALIZUMAB dosage: 1.1 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CLOBEX, COUMADIN, PROTOPIC OINTMENT, WELLBUTRIN. Patient was hospitalized. Patient died on 06/30/2006.
EFALIZUMAB problem was reported by a Health Professional from UNITED KINGDOM on July 18, 2006. Male patient, 52 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: dermatitis exfoliative, gait disturbance, impetigo, pemphigoid. EFALIZUMAB dosage: 0.142 MG/KG, SUBCUTANEOUS. During the same period patient was treated with CYCLOSPORINE. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Aug 08, 2006. Male patient, weighting 374.8 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: platelet count decreased. EFALIZUMAB dosage: 170 MG WEEKLY SQ. During the same period patient was treated with NEURONTIN, AMBIEN, LASIX, VITAMIN B. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED STATES on July 27, 2006. Female patient, 26 years of age, weighting 240.3 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, aspartate aminotransferase increased, asthenia, back pain, blood alkaline phosphatase increased, blood bilirubin increased, blood chloride increased, blood glucose increased, blood ph decreased. EFALIZUMAB dosage: unknown. During the same period patient was treated with CLOBEX, COUMADIN, PROTOPIC OINTMENT, WELLBUTRIN, TOPICAL STEROIDS. Patient was hospitalized. Patient died on 06/30/2006.
Physician from SWITZERLAND reported EFALIZUMAB problem on Aug 02, 2006. Male patient, 67 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: follicular mucinosis. EFALIZUMAB dosage: 0.142 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with NEBIVOLOL, LEVOTHYROXINE, DOXAZOSIN MESYLATE. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED KINGDOM on Aug 15, 2006. Male patient, 43 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: condition aggravated, dermatitis, hyperkeratosis, lymphocytosis, parakeratosis, psoriasis, rash erythematous, rash pruritic, skin erosion. EFALIZUMAB dosage: 0.142 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CALCIPOTRIOL, AQUEOUS CREAM. Patient recovered.
Health Professional from AUSTRIA reported EFALIZUMAB problem on Aug 11, 2006. Male patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: epididymitis. EFALIZUMAB dosage: 0.7 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with HYDROCHLOROTHIAZIDE, FUROSEMIDE, OLMESARTAN, SIMVASTATIN, ALLOPURINOL, ETOFYLLINE, CAPTOPRIL. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from AUSTRIA on Aug 22, 2006. Male patient, 40 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: hepatitis b, hepatotoxicity. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with ENBREL. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from SWITZERLAND reported EFALIZUMAB problem on Sept 05, 2006. Male patient, 43 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: condition aggravated, dermatitis, hyperkeratosis, lymphocytosis, parakeratosis, psoriasis, rash erythematous, rash pruritic, skin erosion. EFALIZUMAB dosage: 0.142 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CALCIPOTRIOL, AQUEOUS CREAM. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from SWITZERLAND on Sept 05, 2006. Male patient, 40 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: hepatitis b, hepatotoxicity. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with ENBREL. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Sept 18, 2006. Female patient, 26 years of age, weighting 240.3 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, aspartate aminotransferase increased, back pain, blood alkaline phosphatase increased, blood bilirubin increased, blood chloride increased, blood glucose increased, blood pressure increased, blood sodium decreased. EFALIZUMAB dosage: 1.1 ML, 1/WEEK, SUBCUTANEOUS, SEE IMAGE. During the same period patient was treated with CLOBEX, COUMADIN, PROTOPIC OINTMENT, WELLBUTRIN, TOPICAL STEROIDS. Patient was hospitalized. Patient died on 06/30/2006.
EFALIZUMAB problem was reported by a Consumer or non-health professional from BRAZIL on Sept 22, 2006. Male patient, 46 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthritis, asthenia, asthma, basophil count increased, blood potassium increased, condition aggravated, eosinophil count increased, hypertension, hypochromic anaemia. EFALIZUMAB dosage: 0.142 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
Physician from BRAZIL reported EFALIZUMAB problem on Sept 20, 2006. Male patient, 37 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, blood cholesterol increased, blood glucose abnormal, blood triglycerides increased, diabetes mellitus, gamma-glutamyltransferase increased, glycosylated haemoglobin increased, hepatic enzyme increased, high density lipoprotein decreased. EFALIZUMAB dosage: 0.142 MG/KG SUBCUTANEOUS. Patient recovered.
EFALIZUMAB problem was reported by a Physician from AUSTRIA on Sept 22, 2006. Male patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: epididymitis. EFALIZUMAB dosage: 0.7 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with HYDROCHLOROTHIAZIDE, FUROSEMIDE, OLMESARTAN, SIMVASTATIN, ALLOPURINOL, ETOFYLLINE, CAPTOPRIL. Patient was hospitalized. Patient recovered.
Physician from BRAZIL reported EFALIZUMAB problem on Sept 25, 2006. Female patient, 34 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: bile duct stone, cholecystitis chronic, cholelithiasis, condition aggravated. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED STATES on Sept 22, 2006. Male patient, 78 years of age, weighting 156.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: hepatic neoplasm malignant, splenomegaly, varices oesophageal. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with METHOTREXATE, ADALIMUMAB, LISINOPRIL. Patient recovered.
Physician from UNITED STATES reported EFALIZUMAB problem on Sept 28, 2006. Female patient, 26 years of age, weighting 240.3 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: back pain, brain stem syndrome, central nervous system necrosis, coma, encephalitis viral, hepatic steatosis, hepatitis. EFALIZUMAB dosage: 1.1 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CLOBEX, COUMADIN, PROTOPIC OINTMENT. Patient was hospitalized. Patient died on 06/30/2006.
EFALIZUMAB problem was reported by a Health Professional from UNITED STATES on Sept 22, 2006. Male patient, 28 years of age, weighting 155.4 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, anorexia, arthralgia, asthenia, calcinosis, condition aggravated, diverticulum intestinal, granuloma, haemangioma of liver. EFALIZUMAB dosage: 1 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with PREDNISONE, CYCLOSPORINE, REMICADE, BENADRYL. Patient was hospitalized. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Sept 22, 2006. Male patient, 78 years of age, weighting 156.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: hepatic neoplasm malignant, splenomegaly, varices oesophageal. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with METHOTREXATE, ADALIMUMAB, LISINOPRIL. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Oct 19, 2006. Female patient, 26 years of age, weighting 240.3 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: aggression, areflexia, arthralgia, aspartate aminotransferase increased, asthenia, back pain, blood alkaline phosphatase increased, blood bilirubin increased, blood chloride increased. EFALIZUMAB dosage: 1.1 ML, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CLOBEX, COUMADIN, PROTOPIC OINTMENT, WELLBUTRIN, TOPICAL STEROIDS. Patient was hospitalized. Patient died on 06/30/2006.
Consumer or non-health professional from UNITED KINGDOM reported EFALIZUMAB problem on Oct 18, 2006. Male patient, 57 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, eczema. EFALIZUMAB dosage: 0.142 MG/KG, 1/WEEK, SUBCUTANEOUS. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Oct 23, 2006. Male patient, 78 years of age, weighting 156.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: hepatic neoplasm malignant, splenomegaly, varices oesophageal. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with METHOTREXATE, ADALIMUMAB, LISINOPRIL. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Oct 27, 2006. Male patient, 47 years of age, weighting 138.2 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, back pain, calcinosis, computerised tomogram abdomen abnormal, gout, lymphadenopathy, night sweats, polyarthritis, prostate examination abnormal. EFALIZUMAB dosage: 70 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with COLACE, ULTRAVATE CREAM, DOVONEX CREAM, FLUOCINOLONE LOTION, CLOBEX, PROTONIX. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED STATES on Nov 06, 2006. Male patient, 28 years of age, weighting 155.4 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, anorexia, arthralgia, asthenia, diverticulum intestinal, inflammation, joint swelling, lymphocyte percentage decreased, neutrophil percentage increased. EFALIZUMAB dosage: 1 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with PREDNISONE, CYCLOSPORINE, REMICADE, BENADRYL. Patient was hospitalized. Patient recovered.
Physician from UNITED KINGDOM reported EFALIZUMAB problem on Nov 03, 2006. Male patient, 57 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, blood culture positive, eczema, erythrodermic psoriasis, joint swelling, pustular psoriasis, staphylococcal infection. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with NIFEDIPINE. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED KINGDOM on Nov 03, 2006. Male patient, 43 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: blood cholesterol increased, blood pressure systolic increased, condition aggravated, dermatitis, hyperkeratosis, lymphocytosis, psoriasis, skin erosion. EFALIZUMAB dosage: 0.142 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with CALCIPOTRIOL, AQUEOUS CREAM. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported EFALIZUMAB problem on Nov 06, 2006. Male patient, 55 years of age, weighting 245.4 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: anorexia, chills, diverticulitis, encephalitis, headache, herpes virus infection, immune system disorder, meningitis viral, neck pain. EFALIZUMAB dosage: 1 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with ZOLOFT, ATENOLOL, METHOTREXATE, FOLIC ACID, METFORMIN, TRICOR, MIMYX CREAM, SALEX CREAM. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Consumer or non-health professional from UNITED STATES on Nov 20, 2006. Female patient, 33 years of age, weighting 185.0 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: abortion spontaneous. EFALIZUMAB dosage: 0.8 MG, 1/WEEK, SUBCUTANEOUS. Patient recovered.
Health Professional from UNITED STATES reported EFALIZUMAB problem on Dec 05, 2006. Male patient, 47 years of age, weighting 138.2 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: back pain, computerised tomogram abnormal, gouty arthritis, hyperhidrosis, lymphadenopathy, polyarthritis, prostate examination abnormal, psoriatic arthropathy, systemic inflammatory response syndrome. EFALIZUMAB dosage: 70 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with COLACE, ULTRAVATE CREAM, DOVONEX CREAM, FLUOCINOLONE LOTION, CLOBEX, PROTONIX. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Health Professional from UNITED STATES on Dec 05, 2006. Male patient, 28 years of age, weighting 155.4 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, anorexia, asthenia, condition aggravated, diverticulum intestinal, haemangioma, inflammation, liver disorder, platelet count increased. EFALIZUMAB dosage: 1 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with PREDNISONE, CYCLOSPORINE, REMICADE, BENADRYL. Patient was hospitalized. Patient recovered.
Health Professional from SWITZERLAND reported EFALIZUMAB problem on Dec 01, 2006. Male patient, 57 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: arthralgia, blood culture positive, eczema, erythrodermic psoriasis, rash pruritic, rash pustular, staphylococcal infection. EFALIZUMAB dosage: 1 MG/KG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with NIFEDIPINE. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Dec 12, 2006. Female patient, 61 years of age, weighting 205.0 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: papillary thyroid cancer. EFALIZUMAB dosage: unknown. During the same period patient was treated with SYNTHROID, CYTOMEL. Patient was hospitalized. Patient recovered.
Physician from UNITED STATES reported EFALIZUMAB problem on Dec 12, 2006. Female patient, 68 years of age, weighting 205.5 lb, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: ascites, cardiomegaly, clostridium difficile colitis, clostridium difficile sepsis, haematocrit decreased, haemoglobin decreased, heart rate increased, hepatitis c positive, hypotension. EFALIZUMAB dosage: 125 MG, 1/WEEK, SUBCUTANEOUS. During the same period patient was treated with TOPICAL STEROIDS, NORVASC, DETROL LA, LASIX, ACCUPRIL, HYDROCHLOROTHIAZIDE, ACTOS, SINGULAIR. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from SWITZERLAND on June 18, 2007. Male patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, lupus-like syndrome, vitamin b1 deficiency, vitamin b12 deficiency. EFALIZUMAB dosage: unknown. Patient was hospitalized. Patient recovered.
Consumer or non-health professional from UNITED STATES reported EFALIZUMAB problem on June 25, 2007. Male patient, weighting 197.8 lb, was diagnosed with psoriasis, back pain and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: mental status changes. EFALIZUMAB dosage: 0.08 MG, 1/WEEK. During the same period patient was treated with TOPICAL STEROID, KETOCONAZOLE, NPH INSULIN, REGULAR INSULIN, NORCO. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from SWITZERLAND on June 27, 2007. Female patient, 49 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: alanine aminotransferase increased, aspartate aminotransferase increased, b-cell lymphoma, chronic lymphocytic leukaemia. EFALIZUMAB dosage: unknown. Patient recovered.
Physician from SWITZERLAND reported EFALIZUMAB problem on July 05, 2007. Female patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: endometrial cancer. EFALIZUMAB dosage: 1 MG, 1/WEEK. Patient recovered.
EFALIZUMAB problem was reported by a Physician from SWITZERLAND on July 20, 2007. Male patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: anaemia, lupus-like syndrome, vitamin b1 deficiency, vitamin b12 deficiency. EFALIZUMAB dosage: unknown. Patient was hospitalized. Patient recovered.
Physician from SWITZERLAND reported EFALIZUMAB problem on Aug 02, 2007. Male patient, 62 years of age, was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: rhabdomyolysis. EFALIZUMAB dosage: unknown. During the same period patient was treated with FOSINOPRIL, PRAVASTATIN. Patient was hospitalized. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Sept 04, 2007. Female patient, weighting 175.4 lb, was diagnosed with psoriasis, irritable bowel syndrome and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. EFALIZUMAB dosage: 1 MG, 1/WEEK. During the same period patient was treated with TOPICAL STEROID NOS, DYAZIDE, CALCIUM, ALLEGRA D, BENTYL. Patient was hospitalized. Patient recovered.
Physician from SWITZERLAND reported EFALIZUMAB problem on Sept 21, 2007. Male patient was diagnosed with psoriasis and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: endocarditis. EFALIZUMAB dosage: 1.3 ML, 1/WEEK. Patient was hospitalized and became disabled. Patient recovered.
EFALIZUMAB problem was reported by a Physician from UNITED STATES on Sept 04, 2007. Female patient, weighting 175.4 lb, was diagnosed with psoriasis, irritable bowel syndrome and was treated with EFALIZUMAB. After drug was administered, patient experienced the following problems/side effects: pulmonary embolism. EFALIZUMAB dosage: 1 MG, 1/WEEK. During the same period patient was treated with TOPICAL STEROID NOS, DYAZIDE, CALCIUM, ALLEGRA D, BENTYL. Patient was hospitalized. Patient recovered.